Bifidobacterium bifidum and IBS

What 2 graded rows on bifidobacterium bifidum agree on for IBS, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Bifidobacterium bifidum page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Bifidobacterium bifidum page, with its PubMed record.

Supplement

Bifidobacterium bifidum Choose another

2 rows · 565 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade B, is a randomized trial of 443 people (2020) and found an improvement.

The rows run from 122 to 443 people, published from 2011 to 2020: 2 single studies.

2 improved

Grade BAbdominal pain plus adequate relief of IBS symptoms · Improved
RCT · n 443 · 2020 · Adults with IBS (Rome III) at 20 sites in Germany
1 billion cells a day · 8 weeks
34% reached the combined endpoint of at least 30% less pain plus adequate relief in 4 of 8 weeks, versus 19% on placebo (risk ratio 1.7). Suspected product-related adverse events were similar (7 vs 8), with no serious ones.
Row on the Bifidobacterium bifidum page · PubMed 32277872 (opens PubMed)
Grade BGlobal IBS symptoms · Improved
RCT · n 122 · 2011 · Adults with IBS
Once daily (CFU not stated in the abstract) · 4 weeks
Global IBS symptoms fell 0.88 points on a 7-point scale versus 0.16 with placebo. Adequate relief: 47% vs 11%; responders: 57% vs 21%. Pain, bloating and urgency also improved, and adverse events did not differ.
Row on the Bifidobacterium bifidum page · PubMed 21418261 (opens PubMed)